论文部分内容阅读
冠心病是临床上比较常见的疾病,治疗手段多种多样.体外反博(ECP)作为一种治疗冠心病的新型手段,已经受到国内外学者广泛的重视.自1962年Soroff等人率先制成对人体无创伤性的体外反搏装置,用于治疗急性心肌梗塞早期及心绞痛病人以来,无论从体外反搏装置及临床应用方面已有很大进展.文献报道冠心病在行体外反搏治疗后,无论在临床症状或心电图ST-T方面,均有较明显的改善.目前对体外反搏治疗冠心病所产生的心功能影响的评价不一,对体外反搏治疗整个疗程后产生的
Coronary heart disease is a relatively common clinical disease, a variety of treatment methods.External anti-Bo (ECP) as a new means of treatment of coronary heart disease, has received widespread attention of scholars at home and abroad.Soloff et al. On the human noninvasive EECP device for the treatment of early and acute myocardial infarction patients with angina pectoris, both from the ECP device and clinical application has made great progress in the literature reported coronary heart disease after ex vivo counterpulsation , Both in clinical symptoms or ECG ST-T, there are more significant improvements.Currently, the impact of extracorporeal counter-pacing in the treatment of coronary heart disease have different evaluation of cardiac function, the external counterpulsation after the entire course of treatment generated